Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly’s rival, Johnson & Johnson (JNJ) shares lagged behind the stock, with a 13.2% gain on a YTD basis and a 1.7% return over the past 52 weeks. Wall Street analysts are bullish on LLY’s ...

If you wait for a top growth stock to come down to a P/E of 20 or less, you may end up waiting forever and missing out on the opportunity completely. For years, Eli Lilly has been generating solid ...

We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look ...

Approval for orforglipron would not only generate a lot of bullishness for the healthcare stock, but would also provide Eli Lilly with yet another blockbuster drug, and potentially enable it to ...